K. S. Shah, H. Xu, and R. A. Matsouaka, Heart Failure With Preserved, Borderline, and 406 Reduced Ejection Fraction: 5-Year Outcomes, J Am Coll Cardiol, 2017.

D. A. Alter, D. T. Ko, and J. V. Tu, The average lifespan of patients discharged from hospital 409 with heart failure, J Gen Intern Med, 2012.

S. J. Greene, J. Butler, and N. M. Albert, Medical Therapy for Heart Failure With Reduced 411 Ejection Fraction: The CHAMP-HF Registry, J Am Coll Cardiol, 2018.

M. Komajda, J. Schöpe, and S. Wagenpfeil, Physicians' guideline adherence is associated 414 with long-term heart failure mortality in outpatients with heart failure with reduced 415 ejection fraction: the QUALIFY international registry, Eur J Heart Fail, 2019.

H. P. Brunner-la-rocca, G. C. Linssen, and F. J. Smeele, Contemporary Drug Treatment of 418

, Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry, JACC, vol.419

, Hear Fail, 2019.

F. Zannad, J. Mcmurray, and H. Krum, Eplerenone in patients with systolic heart failure 421

B. Pitt, F. Zannad, and W. J. Remme, The effect of spironolactone on morbidity and 423 mortality in patients with severe heart failure

, N Engl J Med, 1999.

J. Mcmurray, S. D. Solomon, and S. E. Inzucchi, Dapagliflozin in patients with heart 426 failure and reduced ejection fraction, N Engl J Med, 2019.

J. Mcmurray, M. Packer, and A. S. Desai, Angiotensin-Neprilysin Inhibition versus 428

, Enalapril in Heart Failure, N Engl J Med, vol.371, pp.993-1004, 2014.

M. Vaduganathan, G. C. Fonarow, and S. J. Greene, Contemporary Treatment Patterns, p.430

, Clinical Outcomes of Comorbid Diabetes Mellitus and Heart Failure with Reduced 431

, Ejection Fraction: the CHAMP-HF Registry, JACC Heart Fail, vol.2020

S. J. Greene, G. C. Fonarow, and A. D. Devore, Longitudinal Titration of Medical Therapy 433 for Heart Failure with Reduced Ejection Fraction: CHAMP-HF Registry, J Am Coll 434 Cardiol, 2019.

C. W. Tsao, A. Lyass, and D. Enserro, Temporal Trends in the Incidence of and Mortality 436

, Associated With Heart Failure With Preserved and Reduced Ejection Fraction, JACC, vol.437

, Hear Fail, 2018.

J. Mcmurray, M. Packer, and A. S. Desai, Angiotensin-neprilysin inhibition versus 439 enalapril in heart failure, N Engl J Med, 2014.

L. D. Fisher, M. Gent, and H. R. Büller, Active-control trials: How would a new agent compare 441 with placebo? A method illustrated with clopidogrel, aspirin, and placebo, Am Heart J, vol.442, 2001.

S. Durrleman and P. Chaikin, The use of putative placebo in active control trials: Two 444 applications in a regulatory setting, Stat Med, 2003.

V. Hasselblad and D. F. Kong, Statistical methods for comparison to placebo in active-control 446 trials, Ther Innov Regul Sci, 2001.

J. Mcmurray, M. Packer, and A. Desai, A putative placebo analysis of the effects of 448 LCZ696 on clinical outcomes in heart failure, Eur Heart J, 2015.

B. Claggett, M. Packer, and J. Mcmurray, Estimating the long-term treatment benefits 451 of sacubitril-valsartan, N Engl J Med, 2015.

, Am Coll Cardiol, 2019.

J. P. Ferreira, X. Rossello, and R. Eschalier, MRAs in Elderly HF Patients: Individual, vol.455

R. Patient-data-meta-analysis-of, T. Empahsis-hf, and . Jacc, Hear Fail, vol.456, p.2019

P. S. Jhund, M. Fu, and E. Bayram, Efficacy and safety of LCZ696 (sacubitril-valsartan) 458 according to age: Insights from PARADIGM-HF, Eur Heart J, vol.36, pp.2576-84, 2015.

F. A. Martinez, M. Serenelli, and J. C. Nicolau, Efficacy and Safety of Dapagliflozin in Heart 460

, Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

, Circulation, 2020.

H. Burnett, A. Earley, and A. A. Voors, Thirty Years of Evidence on the Efficacy of Drug 463

, Treatments for Chronic Heart Failure with Reduced Ejection Fraction: A Network Meta-464

, Circ Hear Fail, Analysis, 2017.

A. S. Desai, O. Vardeny, and B. Claggett, Reduced Risk of hyperkalemia during treatment 466 of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan 467 compared with enalapril: A secondary analysis of the PARADIGM-HF trial, JAMA 468 Cardiol, 2017.

A. A. Bhagat, S. J. Greene, M. Vaduganathan, and G. C. Fonarow, , p.470

, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization

, JACC Heart Fail, 2019.

M. Vaduganathan, M. Gheorghiade, and J. Butler, Expanding the scope of the 'polypill' to heart 473 failure, J Card Fail, 2013.

J. Paladino, J. R. Lakin, and J. J. Sanders, Communication Strategies for Sharing Prognostic 475 Information with Patients: Beyond Survival Statistics

, Pfizer Data Access Requests

. Accessed, , 2020.

, Novartis Position on Clinical Study Transparency -Clinical Study Registration, Results 481 Reporting and Data Sharing